Summary
The results are reported of a controlled, double-blind, crossover trial of piperazine oestrone sulphate (‘Harmogen’) compared with ethinyl oestradiol and placebo in menopausal patients with features of endogenous oestrogen withdrawal. The oestro-genicity of both active substances was well substantiated by vaginal epithelial maturation indices. Piperazine oestrone sulphate was superior to ethinyl oestradiol, at the dosage levels used, in producing a more pronounced relief of menopausal symptoms without any notable adverse effects. The incidence of side-effects was greater during treatment with ethinyl oestradiol. Piperazine oestrone sulphate is considered to be at least as effective an oestrogenic substance as ethinyl oestradiol and worthy of further therapeutic evaluation.